Abstracts Archive - Page 1765 of 2607 - ACR Meeting Abstracts

Abstract Number: 2493 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Lorie A. Ellis¹, Raphael J. DeHoratius², Shelly Kafka³, Helen Varker⁴, Matthew Brouillette⁴ and Elisabetta Malangone-Monaco⁴, ¹Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Truven Health Analytics, Bethesda, MD
Background/Purpose: Infliximab (IFX) and golimumab (GLM-IV) for intravenous use are anti-TNF agents indicated for rheumatoid arthritis (RA) and differ in weight-based dose, induction schedule, and…
Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
J Fransen¹, L Tweehuysen², A den Broeder³, R Postema⁴, E Alemao⁵ and F van den Hoogen⁶, ¹Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ²Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Rheumatology, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Josef Smolen¹, Yihan Li², Iain Sainsbury², Stefan Florentinus², Kershnie Rambalee² and GR Burmester³, ¹Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 2497 • 2016 ACR/ARHP Annual Meeting
Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
Cecilia Lourdudoss¹, Alicja Wolk², Lena Nise³, Lars Alfredsson⁴ and Ronald F. van Vollenhoven¹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ²Unit of Nutritional Epidemiology, Dept of Environmental Medicine, Karolinska institutet, Stockholm, Sweden, ³Unit of Cardiovascular Epidemiology, Dept of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: We hypothesized that increased dietary intake of vitamin D and omega-3 fatty acids (FA) prior to disease modifying anti-rheumatic drug (DMARD) initiation may associate…
Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Hilde B. Hammer², Till Uhlig¹, Desiree van der Heijde^1,3, Tore K Kvien¹ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2500 • 2016 ACR/ARHP Annual Meeting
Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam^2,3, Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Clinical Epidemiology unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The Swedish Society for Rheumatology guidelines recommend remission as treatment goal for patients with rheumatoid arthritis (RA). The Swedish quality registry (SRQ) is a…
Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Ruediger Mueller¹, Katja Heinimann², Rafael Sauter³, Hendrik Schulze-Koops⁴, Tuulikki Sokka-Isler⁵, Michael Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Rheumatology, University of Colorado, Denver, CO, ⁷Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…
Abstract Number: 2502 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Kaita Sugiyama⁴, Yosuke Nagasawa⁵, Hirotake Inomata⁴, Natsumi Ikumi⁶, Atsuma Nishiwaki⁴, Takamasa Nozaki¹, Noboru Kitamura⁵ and Masami Takei⁵, ¹Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ⁴Nihon University School of Medicine, Tokyo, Japan, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Shinjuku, Japan
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a two-fold higher risk of sudden death than the healthy age- and sex-matched general population. Although the underlying…
Abstract Number: 2503 • 2016 ACR/ARHP Annual Meeting
Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
Iris Navarro-Millán¹, Ronan O'Beirne², Melanie Morris³, Bernadette Johnson¹, James Willig⁴, Huifeng Yun⁵, Andrea Cherrington⁶, Liana Fraenkel⁷, Monika M. Safford⁸ and Jeffrey Curtis⁹, ¹Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Continuing Medical Education, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Yale University School of Medicine, New Haven, CT, ⁸Weill Cornell Medical College, New York, NY, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Little is known on what subjective or objective data that rheumatologists consider most important for them to inform their treatment decisions for patients…
Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 2506 • 2016 ACR/ARHP Annual Meeting
Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2, Susan Lester³, Sunil Nagpal⁴, Jessica Peters⁵, Anuk Das⁶, Pravin Hissaria^7,8, Tania Crotti⁹, Llew Spargo¹⁰, Jennifer G Walker^1,2,10, Malcolm D. Smith¹ and Susanna M Proudman^9,10, ¹Flinders University, Adelaide, Australia, ²Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ³Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁴Immunology, Janssen Research & Development, Spring House, PA, ⁵Janssen Research & Development, Spring House, PA, ⁶Janssen R&D, Berwyn, PA, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Immunology, SA Pathology, Adelaide, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: There are limited data regarding the role of and response to treatment, of bone biomarkers in early rheumatoid arthritis (RA) treated with conventional DMARDs.…
Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].